ImmuPharma And Simbec-Orion Collaborate And Start Pivotal Phase III Lupuzorâ„¢ Study
ImmuPharma PLC and Simbec-Orion Group Limited recently announced a collaboration agreement for the execution of a Pivotal Phase III clinical study of ImmuPharma’s Lupuzorâ„¢, the company’s lead compound to treat Systemic Lupus Erythematosus, a chronic and life-threatening autoimmune disease. Lupuzor was granted Fast Track status by the Food and Drugs Administration (FDA); it…